Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Clin Transl Oncol. 2020 Jan;22(1):11-20. doi: 10.1007/s12094-019-02136-5. Epub 2019 May 29.
The advent of molecular therapy through targeted kinase inhibitors (TKI) has revolutionized the management of renal cell carcinoma. Although surgical resection remains the cornerstone of any therapeutic plan, an increased risk of morbidity and mortality can be of concern in large and complex bulky tumors. Preoperative therapy with TKIs is hypothesized to facilitate resectability, reduce surgical morbidity and allow nephron-sparing surgery. Many concerns on the safety, efficacy and tolerability of these agents before surgery have halted the progress in this setting. In this paper, we will review the indications and safety of preoperative TKIs in RCC as well as the future approaches.
分子治疗的出现，通过靶向激酶抑制剂（TKI），彻底改变了肾细胞癌的治疗方式。虽然手术切除仍然是任何治疗计划的基石，但在大型和复杂的肿块肿瘤中，发病率和死亡率的增加可能令人担忧。术前 TKI 治疗被假设可以提高可切除性，降低手术发病率，并允许保留肾单位手术。在术前使用这些药物的安全性、疗效和耐受性方面存在许多担忧，这阻碍了该领域的进展。在本文中，我们将回顾 RCC 术前 TKI 的适应证和安全性，以及未来的方法。
